Our proprietary StaR® technology and SBDD platform has enabled us to develop small molecules, peptides and antigens for antibody discovery. To date, we have leveraged our technologies and expertise to create a pipeline of drug candidates targeting GPCRs that we believe have potential to become first-in-class or best-in-class medicines in therapeutic areas such as neurodegenerative and neurological diseases, next-generation immuno-oncology approaches, gastroenterology, inflammation and rare or orphan diseases.
Our partnered pipeline includes drug candidates that we have out-licensed to leading pharmaceutical and biotechnology companies, including AstraZeneca and Allergan; and drug candidates for which we have ongoing collaboration projects, including with Pfizer, Daiichi Sankyo and MorphoSys. Our partners are developing one or more drug candidates that we discovered using our SBDD platform. We believe these strategic partnerships validate our GPCR technologies and SBDD platform capabilities, and also provide a diversified source of revenues in the form of up-front and milestone payments.
Our partnered pipeline also includes drug candidates that we are currently co-developing, or which we plan to co-develop, with collaboration partners under profit and risk-sharing arrangements. We have entered into strategic co-development agreements with Kymab and PeptiDream, for the discovery, development and commercialization of certain novel antibody therapeutics and peptides.
Our emerging pipeline of in-house programs comprises drug candidates advancing through various stages of early development and preclinical studies with a focus on core therapeutic areas including neurology, gastro-intestinal, inflammatory and other indications. Our plan is to advance only the highest quality programs from our proprietary pipeline to clinical development, with the intent to eventually commercialize selected products in designated markets ourselves.